April 2024
1. CAIRO MS
   TP3 binding domain mutations are bad news in Burkitt lymphoma.
   Haematologica. 2024 Apr 18. doi: 10.3324/haematol.2024.285213.
   

   >> Share

   
   
2. BOURLON C, Roddie C, Menne T, Norman J, et al
   Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.
   Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285010.
   

   >> Share

   
   
3. IKEDA D, Oura M, Uehara A, Tabata R, et al
   Prognostic relevance of tumor-infiltrating CD4(+) cells and total metabolic tumor volume-based risk stratification in diffuse large B-cell lymphoma.
   Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285038.
   

   >> Share

   
   March 2024
4. BI C, Huang Y, Ali R, Wang F, et al
   MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications.
   Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2023.283811.
   

   >> Share

   
   
5. PULCZYNSKI EJ, Simonsen MR, Kuittinen O, Fagerli UM, et al
   Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up.
   Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.285207.
   

   >> Share

   
   
6. WIGHT J, Blombery P, Lickiss J, Burgess M, et al
   Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillance.
   Haematologica. 2024 Mar 21. doi: 10.3324/haematol.2023.284600.
   

   >> Share

   
   
7. IANNITTO E, Ferrero S, Bommier C, Drandi D, et al
   Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
   Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109.
   

   >> Share

   
   
8. ZHU ML, Drill E, Joffe E, Salles G, et al
   Validation of LymphGen classification on a 400-gene clinical next-generation sequencing panel in diffuse large B-cell lymphoma: real-world experience from a cancer center.
   Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284565.
   

   >> Share

   
   
9. TOLLEY ER, Lewinter C, Pedersen LM, Nielsen TH, et al
   Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis.
   Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284281.
   

   >> Share

   
   
10. BARRACLOUGH A, Agrawal S, Talaulikar D, Chong G, et al
    Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study.
    Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284538.
    

    >> Share

    
    February 2024
11. DURAND R, Bellanger C, Kervoelen C, Tessoulin B, et al
    Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma.
    Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284345.
    

    >> Share

    
    
12. MARTIRE G, Lovisa F, Carraro E, Rizzato D, et al
    TP53 DNA binding domain mutational status and rituximab-based treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification.
    Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284868.
    

    >> Share

    
    
13. STATHIS A, Pirosa MC, Orsucci L, Feugier P, et al
    IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
    Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283918.
    

    >> Share

    
    
14. YUAN X, Xie Y, Xu N, Liu H, et al
    Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma.
    Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284834.
    

    >> Share

    
    
15. SAVAGE KJ, De Leval L
    Erratum to: Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization.
    Haematologica. 2024;109:693-694.
    

    >> Share

    
    
16. KUPPERS R
    Distinct t(14;19) translocation patterns in atypical chronic lymphocytic leukemia and marginal zone lymphomas.
    Haematologica. 2024;109:376-378.
    

    >> Share

    
    
17. CARBO-MEIX A, Guijarro F, Wang L, Grau M, et al
    BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases.
    Haematologica. 2024;109:493-508.
    

    >> Share

    
    January 2024
18. DESMARES A, Bouzy S, Thonier F, Goustille J, et al
    Hepatosplenic T-cell lymphoma displays an original oyster-shell cytological pattern and a distinct genomic profile from that of gamma-delta T-cell large granular lymphocytic leukemia.
    Haematologica. 2024 Jan 25. doi: 10.3324/haematol.2023.283856.
    

    >> Share

    
    
19. TUN AM, Wang Y, Maliske S, Micallef I, et al
    Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy.
    Haematologica. 2024 Jan 18. doi: 10.3324/haematol.2023.284704.
    

    >> Share

    
    
20. SAVAGE KJ, Slack GW
    Erratum to: DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome.
    Haematologica. 2024;109:365.
    

    >> Share

    
    December 2023
21. SAVAGE KJ, De Leval L
    Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization.
    Haematologica. 2023;108:3204-3210.
    

    >> Share

    
    
22. LEWIS NE, Zhou T, Dogan A
    Biology and genetics of extranodal mature T-cell and NKcell lymphomas and lymphoproliferative disorders.
    Haematologica. 2023;108:3261-3277.
    

    >> Share

    
    
23. STUVER R, Epstein-Peterson ZD, Horwitz SM
    Few and far between: clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas.
    Haematologica. 2023;108:3244-3260.
    

    >> Share

    
    
24. BISIG B, Savage KJ, De Leval L
    Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions.
    Haematologica. 2023;108:3227-3243.
    

    >> Share

    
    
25. NGU HS, Savage KJ
    Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas.
    Haematologica. 2023;108:3211-3226.
    

    >> Share

    
    
26. LACAN C, Caron J, Tarantino N, Fouquet B, et al
    CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes.
    Haematologica. 2023;108:3485-3490.
    

    >> Share

    
    
27. ZHANG L, Zhu X, Qu W, Lu Y, et al
    Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of PCM1::JAK2 with erythroblastic sarcoma: a case report and literature review.
    Haematologica. 2023;108:3506-3510.
    

    >> Share

    
    November 2023
28. JALLOUK AP, Kui N, Sun R, Westin JR, et al
    Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
    Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.284453.
    

    >> Share

    
    
29. MAURER MJ, Casulo C, Larson MC, Habermann TM, et al
    Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
    Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.283737.
    

    >> Share

    
    
30. CARRAS S, Torroja A, Emadali A, Montaut E, et al
    Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
    Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.283724.
    

    >> Share

    
    
31. BROADBENT R, Crosbie P, Armitage CJ, Taylor B, et al
    Pilot study of lung cancer screening for survivors of Hodgkin lymphoma.
    Haematologica. 2023 Nov 16. doi: 10.3324/haematol.2023.283287.
    

    >> Share

    
    
32. HOFFMANN MS
    Routine consolidation of early stage primary bone lymphoma with radiation therapy does not improve outcomes.
    Haematologica. 2023 Nov 16. doi: 10.3324/haematol.2023.284303.
    

    >> Share

    
    
33. DE CONINCK S, De Smedt R, Lintermans B, Reunes L, et al
    Targeting hyperactive platelet-derived growth factor receptor-beta signaling in T-cell acute lymphoblastic leukemia and lymphoma.
    Haematologica. 2023 Nov 9. doi: 10.3324/haematol.2023.283981.
    

    >> Share

    
    
34. MAYR F, Kruse V, Fuhrmann DC, Wolf S, et al
    SH2 domain-containing inositol 5-phosphatases support the survival of Burkitt lymphoma cells by promoting energy metabolism.
    Haematologica. 2023 Nov 2. doi: 10.3324/haematol.2023.283663.
    

    >> Share

    
    
35. MAURER MJ
    The International Prognostic Index in aggressive B-cell lymphoma.
    Haematologica. 2023;108:2874-2879.
    

    >> Share

    
    
36. LEIVONEN SK, Friman T, Autio M, Vaittinen S, et al
    Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas.
    Haematologica. 2023;108:3044-3057.
    

    >> Share

    
    October 2023
37. LIA K, Jorgensen RRK, L Wold B, Fluge O, et al
    Overall survival and causes of death in elderly patients with Hodgkin lymphoma: a Norwegian population-based case-control study.
    Haematologica. 2023 Oct 26. doi: 10.3324/haematol.2023.283721.
    

    >> Share

    
    
38. KUMAR A
    MYC overexpression: adding another piece to the puzzle of high-risk mantle cell lymphoma.
    Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.284105.
    

    >> Share

    
    
39. REZAZADEH A, Szabo A, Khurana A, Inwards DJ, et al
    Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.
    Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.283210.
    

    >> Share

    
    
40. SONG YQ, Zhang HL, Huang HQ, Zhang QY, et al
    Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma.
    Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.283802.
    

    >> Share

    
    
41. MEEUWES FO, Brink M, Plattel W, Van der Poel MWM, et al
    Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands.
    Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.283174.
    

    >> Share

    
    
42. CROSSWELL HE, LaCasce AS, Bartlett NL, Straus DJ, et al
    Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
    Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.283303.
    

    >> Share

    
    
43. KAWATA T, Shimizu T, Shindo T, Fujiwara K, et al
    Tucidinostat restores CCR4 expression in adult T-cell leukemia/lymphoma.
    Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.283266.
    

    >> Share

    
    
44. HO C, Smith SD
    More than a Lonca-shot: beating the odds in relapsed/refractory diffuse large B-cell lymphoma.
    Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.284056.
    

    >> Share

    
    
45. PASTORCZAK A, Szmyd B, Braun M, Madzio J, et al
    Clinical and laboratory diversity of diffuse large B-cell lymphomas in children with Nijmegen breakage syndrome.
    Haematologica. 2023;108:2808-2813.
    

    >> Share

    
    September 2023
46. KHANLARI M, Wang W, Liu YC, Wang L, et al
    Concurrent peripheral T-cell lymphoma and T-cell lymphoblastic leukemia/lymphoma with identical STIL::TAL1 fusion events.
    Haematologica. 2023 Sep 28. doi: 10.3324/haematol.2023.283585.
    

    >> Share

    
    
47. FLOWERS CR, Matasar MJ, Herrera AF, Hertzberg M, et al
    Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
    Haematologica. 2023 Sep 28. doi: 10.3324/haematol.2023.283557.
    

    >> Share

    
    
48. FEHNIGER TA, Watkins MP, Ezenwajiaku N, Wan F, et al
    A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.
    Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2022.282246.
    

    >> Share

    
    
49. ROSCHEWSKI M, Hodson DJ
    Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.
    Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2021.278613.
    

    >> Share

    
    
50. FUKANO R, Iijima-Yamashita Y, Iwafuchi H, Nakazawa A, et al
    Prognostic value of minimal disseminated disease assessed using digital PCR for 3'ALK assays in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Haematologica. 2023 Sep 7. doi: 10.3324/haematol.2023.282812.
    

    >> Share

    
    
51. LUMINARI S
    Prognostic tools for older patients with diffuse large B-cell lymphoma: complex patients require complex solutions and a personal touch.
    Haematologica. 2023;108:2269-2270.
    

    >> Share

    
    August 2023
52. GHIONE P, Ahsanuddin S, Luttwak E, Varela SB, et al
    Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good long-term outcomes.
    Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2022.282643.
    

    >> Share

    
    
53. EPSTEIN-PETERSON ZD, Drill E, Aypar U, Batlevi CL, et al
    Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
    Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.282898.
    

    >> Share

    
    
54. GORDON LI, Liu FF, Braverman J, Hoda D, et al
    Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study.
    Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283162.
    

    >> Share

    
    
55. SCHULPEN M, Beishuizen A, Chamuleau MED, Dinmohamed AG, et al
    Survival disparities between children and adolescents and young adults for the major subtypes of non-Hodgkin lymphoma in the Netherlands: a large population-based study.
    Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283379.
    

    >> Share

    
    
56. DUELL J, Abrisqueta P, Andre M, Gaidano G, et al
    Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study.
    Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283480.
    

    >> Share

    
    
57. RODRIGUES JM, Hollander P, Schmidt L, Gkika E, et al
    MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 - a Nordic Lymphoma Group study.
    Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283352.
    

    >> Share

    
    
58. COOK MR, Williams LS, Dorris CS, Luo Y, et al
    Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4068 patients.
    Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283446.
    

    >> Share

    
    
59. CAIMI PF, Ai WZ, Alderuccio JP, Ardeshna KM, et al
    Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study.
    Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283459.
    

    >> Share

    
    
60. XIE Z, Lasho T, Khurana A, Ferrer A, et al
    Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy.
    Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283727.
    

    >> Share

    
    
61. RIBERA JM, Morgades M, Garcia-Calduch O, Sirvent M, et al
    Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.
    Haematologica. 2023 Aug 10. doi: 10.3324/haematol.2023.283342.
    

    >> Share

    
    
62. ZHU F, Crombie JL, Ni W, Hoang NM, et al
    Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax.
    Haematologica. 2023 Aug 3. doi: 10.3324/haematol.2023.283245.
    

    >> Share

    
    July 2023
63. LE GOUILL S, Dlugosz-Danecka M, Rule S, Zinzani PL, et al
    Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
    Haematologica. 2023 Jul 20. doi: 10.3324/haematol.2022.282469.
    

    >> Share

    
    
64. GODFREY J, Mei M, Chen L, Song JY, et al
    Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Haematologica. 2023 Jul 20. doi: 10.3324/haematol.2023.283002.
    

    >> Share

    
    
65. IYER SP, Huen A, Ai WZ, Jagadeesh D, et al
    Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.
    Haematologica. 2023 Jul 13. doi: 10.3324/haematol.2022.281875.
    

    >> Share

    
    
66. TAKEUCHI M, Miyoshi H, Semba Y, Yamada K, et al
    Co-stimulatory and immune checkpoint molecules are important in the tumor microenvironment of Hodgkin-like adult T-cell leukemia/lymphoma.
    Haematologica. 2023 Jul 13. doi: 10.3324/haematol.2023.283163.
    

    >> Share

    
    June 2023
67. MULARONI V, Donati B, Tameni A, Manicardi V, et al
    Long non-coding RNA mitophagy and ALK- anaplastic lymphoma associated transcript: a novel regulator of mitophagy in T cell lymphoma.
    Haematologica. 2023 Jun 29. doi: 10.3324/haematol.2022.282552.
    

    >> Share

    
    
68. GANDHI MK, Keane C
    Expanding the bacterial origins of nodular lymphocyte predominant Hodgkin lymphoma.
    Haematologica. 2023 Jun 29. doi: 10.3324/haematol.2023.283392.
    

    >> Share

    
    
69. FITCH BA, Situ J, Wiemels JL, Kogan SC, et al
    Impact of pinworm infection on the development of murine B-cell leukemia/lymphoma in the presence and absence of ETV6::RUNX1.
    Haematologica. 2023 Jun 22. doi: 10.3324/haematol.2022.282591.
    

    >> Share

    
    
70. SAIFI O, Breen WG, Lester SC, Rule WG, et al
    Consolidative radiotherapy for residual FDG activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma.
    Haematologica. 2023 Jun 15. doi: 10.3324/haematol.2023.283311.
    

    >> Share

    
    
71. ABABNEH HS, Ng AK, Frigault MJ, Abramson JS, et al
    Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR Tcell therapy.
    Haematologica. 2023 Jun 15. doi: 10.3324/haematol.2023.282804.
    

    >> Share

    
    
72. CROMBIE JL, Jacobson CA, Redd R, Shouse G, et al
    Prognostic value of early PET in patients with large B-cell lymphoma treated with anti-CD19 CAR T-cell therapy.
    Haematologica. 2023 Jun 1. doi: 10.3324/haematol.2022.282345.
    

    >> Share

    
    
73. SAVAGE KJ, Slack GW
    DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome.
    Haematologica. 2023;108:1463-1467.
    

    >> Share

    
    May 2023
74. GORDON MJ, Bond DA, Kittai AS, Amirmokhtari N, et al
    TRES, a validated three-factor comorbidity score, is associated with survival in older patients with mantle cell lymphoma.
    Haematologica. 2023 May 25. doi: 10.3324/haematol.2023.283074.
    

    >> Share

    
    
75. MULVEY E, Leonard JP
    Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade?
    Haematologica. 2023 May 18. doi: 10.3324/haematol.2023.282893.
    

    >> Share

    
    
76. DECROOS A, Cheminant M, Bruneau J, Carras S, et al
    KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.
    Haematologica. 2023 May 11. doi: 10.3324/haematol.2022.282220.
    

    >> Share

    
    
77. THURNER L, Fadle N, Regitz E, Roth S, et al
    B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma.
    Haematologica. 2023 May 4. doi: 10.3324/haematol.2023.282698.
    

    >> Share

    
    
78. BARZ MJ, Behrmann L, Capron D, Zuchtriegel G, et al
    B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow.
    Haematologica. 2023;108:1244-1258.
    

    >> Share

    
    April 2023
79. WAGNER CB, Boucher K, Nedved A, Micallef IN, et al
    Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes.
    Haematologica. 2023 Apr 27. doi: 10.3324/haematol.2023.282780.
    

    >> Share

    
    
80. MOONLA C, Polprasert C, Komvilaisak P, Rattanathammethee T, et al
    Germline HAVCR2 mutations and their relation to the clinical spectrum of subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis: results from a multicenter study and meta-analysis.
    Haematologica. 2023 Apr 13. doi: 10.3324/haematol.2022.282419.
    

    >> Share

    
    
81. MEI MG, Herrera AF
    Can we cure relapsed/refractory Hodgkin lymphoma without a stem cell transplant?
    Haematologica. 2023 Apr 6. doi: 10.3324/haematol.2023.282731.
    

    >> Share

    
    March 2023
82. LIU X, Zhang LL, Qu BL, Zhong QZ, et al
    Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database.
    Haematologica. 2023 Mar 23. doi: 10.3324/haematol.2022.281847.
    

    >> Share

    
    
83. COOPER A, Kline J
    The lymphoma microenvironment comes of age in the R-CHOP era?
    Haematologica. 2023 Mar 16. doi: 10.3324/haematol.2022.282656.
    

    >> Share

    
    
84. WALCZAK P, Choquet S, Dantal J, Boutboul D, et al
    Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients.
    Haematologica. 2023 Mar 9. doi: 10.3324/haematol.2022.282297.
    

    >> Share

    
    
85. ISAKSEN KT, Galleberg R, Mastroianni MA, Rinde M, et al
    The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy.
    Haematologica. 2023 Mar 2. doi: 10.3324/haematol.2022.282289.
    

    >> Share

    
    
86. WAYNE AS, Huynh V, Hijiya N, Rouce RH, et al
    Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.
    Haematologica. 2023;108:747-760.
    

    >> Share

    
    
87. BOMKEN S, Enshaei A, Schwalbe EC, Mikulasova A, et al
    Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.
    Haematologica. 2023;108:717-731.
    

    >> Share

    
    February 2023
88. BARRACLOUGH A, England JT, Villa D, Wight J, et al
    Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance.
    Haematologica. 2023 Feb 23. doi: 10.3324/haematol.2022.281375.
    

    >> Share

    
    
89. BEWARDER M, Kaddu-Mulindwa D, Kos IA, Lesan V, et al
    Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R) - CHOP.
    Haematologica. 2023 Feb 23. doi: 10.3324/haematol.2022.282126.
    

    >> Share

    
    
90. KAMEDA T, Kataoka K, Kamiunten A, Hidaka M, et al
    Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma.
    Haematologica. 2023 Feb 16. doi: 10.3324/haematol.2022.281510.
    

    >> Share

    
    
91. CHEN G, Herr M, Nowak J, Ho C, et al
    Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant.
    Haematologica. 2023;108:615-620.
    

    >> Share

    
    
92. LOPEZ C, Schleussner N, Bernhart SH, Kleinheinz K, et al
    Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B-cell lymphomas.
    Haematologica. 2023;108:543-554.
    

    >> Share

    
    January 2023
93. DING K, Liu H, Ma J, Yang H, et al
    Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial.
    Haematologica. 2023 Jan 26. doi: 10.3324/haematol.2022.282266.
    

    >> Share

    
    
94. DI M, Long JB, Kothari SK, Sethi T, et al
    Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis.
    Haematologica. 2023 Jan 19. doi: 10.3324/haematol.2022.282252.
    

    >> Share

    
    
95. SONG JY, Nwangwu M, He TF, Zhang W, et al
    Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma.
    Haematologica. 2023 Jan 12. doi: 10.3324/haematol.2022.282265.
    

    >> Share

    
    December 2022
96. LURAIN K, Ramaswami R, Marshall V, Castro EMC, et al
    Kaposi sarcoma herpesvirus viral load as a biomarker for leptomeningeal involvement by primary effusion lymphoma.
    Haematologica. 2022 Dec 22. doi: 10.3324/haematol.2022.281472.
    

    >> Share

    
    
97. CHOHAN KL, Young JR, Lester S, Moustafa MA, et al
    End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim-PET.
    Haematologica. 2022 Dec 22. doi: 10.3324/haematol.2022.282115.
    

    >> Share

    
    
98. PIROSA MC, Sassone M, Kiesewetter B, Guillermo AL, et al
    IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma.
    Haematologica. 2022 Dec 22. doi: 10.3324/haematol.2022.281963.
    

    >> Share

    
    
99. KNORR F, Schellekens KPJ, Schoot RA, Landman-Parker J, et al
    Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma.
    Haematologica. 2022 Dec 15. doi: 10.3324/haematol.2022.281896.
    

    >> Share

    
    
100. GERDTSSON AS, Matos Rodrigues J, Eskelund CW, Husby S, et al
     Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors.
     Haematologica. 2022 Dec 15. doi: 10.3324/haematol.2022.281420.
     

     >> Share

     
     
101. LIU Y, Yan F, Jiang VC, Li Y, et al
     Pirtobrutinib and venetoclax combination overcomes resistance to targeted and CAR Tcell therapy in aggressive mantle cell lymphoma.
     Haematologica. 2022 Dec 7. doi: 10.3324/haematol.2022.282031.
     

     >> Share

     
     
102. DLOUHY I, Armengol M, Recasens-Zorzo C, Ribeiro ML, et al
     Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-kappaB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutati
     Haematologica. 2022;107:2990.
     

     >> Share

     
     
103. INVERNIZZI R
     Images from the Haematologica Atlas of Hematologic Cytology: anaplastic large cell lymphoma, ALK-negative.
     Haematologica. 2022;107:2771.
     

     >> Share

     
     
104. SULEMAN A, Liu J, Hicks LK, Drori AK, et al
     Methotrexate cytarabine thiotepa rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience.
     Haematologica. 2022 Dec 1. doi: 10.3324/haematol.2022.282014.
     

     >> Share

     
     
105. DUMONTET C
     Targetting glutaminase to starve lymphoma cells.
     Haematologica. 2022 Dec 1. doi: 10.3324/haematol.2022.282348.
     

     >> Share

     
     
106. GOYAL G, Magnusson T, Wang X, Roose J, et al
     Modern real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large-B cell lymphoma with or without double/triple-hit status in the United States.
     Haematologica. 2022 Dec 1. doi: 10.3324/haematol.2022.281461.
     

     >> Share

     
     
107. SIBON D, Bisig B, Bonnet C, Poullot E, et al
     ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study.
     Haematologica. 2022 Dec 1. doi: 10.3324/haematol.2022.281442.
     

     >> Share

     
     
108. QIU L, Tang G, Li S, Vega F, et al
     DUSP22 rearrangement is associated with distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma.
     Haematologica. 2022 Dec 1. doi: 10.3324/haematol.2022.281222.
     

     >> Share

     
     November 2022
109. HIRAMATSU H, Nosaka K, Kusumoto S, Nakano N, et al
     Landscape of immunoglobulin heavy chain gamma gene class switch recombination in patients with adult T-cell leukemia-lymphoma.
     Haematologica. 2022 Nov 24. doi: 10.3324/haematol.2022.281435.
     

     >> Share

     
     
110. LI L, Nie L, Jordan A, Cai Q, et al
     Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma.
     Haematologica. 2022 Nov 24. doi: 10.3324/haematol.2022.281538.
     

     >> Share

     
     
111. JALLOUK AP, Gouni S, Westin J, Feng L, et al
     Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.
     Haematologica. 2022 Nov 17. doi: 10.3324/haematol.2022.281954.
     

     >> Share

     
     
112. LIU Y, Derkach A, Lewis N, Zhu M, et al
     Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm.
     Haematologica. 2022 Nov 17. doi: 10.3324/haematol.2022.281724.
     

     >> Share

     
     
113. TUCCI A, Merli F, Fabbri A, Marcheselli L, et al
     Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL).
     Haematologica. 2022 Nov 17. doi: 10.3324/haematol.2022.281407.
     

     >> Share

     
     
114. BOBILLO S, Khwaja J, Ferreri AJ, Cwynarski K, et al
     Prevention and management of secondary central nervous system lymphoma.
     Haematologica. 2022 Nov 17. doi: 10.3324/haematol.2022.281457.
     

     >> Share

     
     
115. QIU L, Xu J, Lin P, Cohen EN, et al
     Unique pathologic features and gene expression signatures distinguish blastoid high-grade B-cell lymphoma from B acute lymphoblastic leukemia/lymphoma.
     Haematologica. 2022 Nov 3. doi: 10.3324/haematol.2022.281646.
     

     >> Share

     
     
116. FORGEARD N, Baron M, Caron J, Boccon-Gibod C, et al
     Inflammation in Waldenstrom macroglobulinemia is associated with 6q deletion and need for treatment initiation.
     Haematologica. 2022;107:2720-2724.
     

     >> Share

     
     
117. BACHY E
     Mature T-cell neoplasms and stem cell transplant: the never-ending story.
     Haematologica. 2022;107:2534-2535.
     

     >> Share

     
     October 2022
118. KHWAJA J, Kirkwood AA, Isbell LK, Steffanoni S, et al
     International multicentre retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma.
     Haematologica. 2022 Oct 27. doi: 10.3324/haematol.2022.281640.
     

     >> Share

     
     
119. DOGAN A
     The real risk of secondary non-Hodgkin lymphoma following Classical Hodgkin lymphoma.
     Haematologica. 2022 Oct 20. doi: 10.3324/haematol.2022.281700.
     

     >> Share

     
     
120. GHIONE P, Palomba ML, Ghesquieres H, Bobillo S, et al
     Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study.
     Haematologica. 2022 Oct 20. doi: 10.3324/haematol.2022.281421.
     

     >> Share

     
     
121. BOOT MV, Schaapveld M, Van den Broek EC, Hijmering NJ, et al
     Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nation-wide cohort: Implications for clinical and epidemiological studies Authors.
     Haematologica. 2022 Oct 20. doi: 10.3324/haematol.2022.280840.
     

     >> Share

     
     
122. THUS YJ, De Rooij MFM, Swier N, Beijersbergen RL, et al
     Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.
     Haematologica. 2022 Oct 13. doi: 10.3324/haematol.2022.281668.
     

     >> Share

     
     
123. RAI S, Kim WS, Ando K, Choi I, et al
     Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
     Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.280996.
     

     >> Share

     
     September 2022
124. DEMEL UM, Wirth M, Yousefian S, Zhang L, et al
     Small molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy.
     Haematologica. 2022 Sep 22. doi: 10.3324/haematol.2022.280995.
     

     >> Share

     
     
125. KHWAJA J, D'Sa S, Minnema MC, Kersten MJ, et al
     IgM monoclonal gammopathies of clinical significance: diagnosis and management.
     Haematologica. 2022;107:2037-2050.
     

     >> Share

     
     
126. CABANNES-HAMY A, Brissot E, Leguay T, Huguet F, et al
     High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL.
     Haematologica. 2022;107:2072-2080.
     

     >> Share

     
     
127. WANG X, Su W, Gao Y, Feng Y, et al
     A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas.
     Haematologica. 2022;107:2154-2162.
     

     >> Share

     
     August 2022
128. FISHER KE, Ferguson LS, Coffey AM, Merritt BY, et al
     Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance.
     Haematologica. 2022;107:1880-1890.
     

     >> Share

     
     July 2022
129. FALINI L, Venanzi A, Tini V, Innocente A, et al
     Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis.
     Haematologica. 2022 Jul 28. doi: 10.3324/haematol.2022.281351.
     

     >> Share

     
     
130. ZURKO J, Ramdial J, Shadman M, Ahmed S, et al
     Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
     Haematologica. 2022 Jul 14. doi: 10.3324/haematol.2022.281242.
     

     >> Share

     
     
131. GANDHI MK, Keane C
     CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma.
     Haematologica. 2022 Jul 14. doi: 10.3324/haematol.2022.281440.
     

     >> Share

     
     
132. STEPHENS DM, Li H, Constine LS, Fitzgerald TJ, et al
     Extranodal presentation in limited stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001.
     Haematologica. 2022 Jul 14. doi: 10.3324/haematol.2022.281004.
     

     >> Share

     
     
133. TAYLOR JG, Truelove E, Clear A, Calaminici M, et al
     PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T cell exhaustion.
     Haematologica. 2022 Jul 14. doi: 10.3324/haematol.2022.280014.
     

     >> Share

     
     
134. HAMADANI M
     Did brentuximab vedotin's rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?
     Haematologica. 2022;107:1500-1502.
     

     >> Share

     
     
135. MAJOR A, Kline J, Karrison TG, Fishkin PAS, et al
     Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
     Haematologica. 2022;107:1608-1618.
     

     >> Share

     
     June 2022
136. KWON M, Iacoboni G, Reguera JL, Corral LL, et al
     Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
     Haematologica. 2022 Jun 30. doi: 10.3324/haematol.2022.280805.
     

     >> Share

     
     
137. FUJI S, Yasunaga JI, Watanabe E, Matsuoka M, et al
     Pseudo-progression of adult T-cell leukemia-lymphoma after cord blood transplantation.
     Haematologica. 2022 Jun 23. doi: 10.3324/haematol.2022.281175.
     

     >> Share

     
     
138. ISAEV K, Liu T, Bakhtiari M, Tong K, et al
     In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program.
     Haematologica. 2022 Jun 23. doi: 10.3324/haematol.2022.280900.
     

     >> Share

     
     
139. VELOZA L, Cavalieri D, Missiaglia E, Ledoux-Pilon A, et al
     Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.
     Haematologica. 2022 Jun 16. doi: 10.3324/haematol.2022.281226.
     

     >> Share

     
     
140. GALTIER J, Vercellino L, Chartier L, Olivier P, et al
     PET-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T-cells.
     Haematologica. 2022 Jun 9. doi: 10.3324/haematol.2021.280550.
     

     >> Share

     
     May 2022
141. ROSSI C, Andre M, Dupuis J, Morschhauser F, et al
     High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline.
     Haematologica. 2022 May 31. doi: 10.3324/haematol.2021.280004.
     

     >> Share

     
     
142. MADUGULA KK, Joseph J, DeMarino C, Ginwala R, et al
     Regulation of Human T-cell Leukemia Virus type 1 antisense promoter by Myocyte Enhancer Factor-2C in the context of Adult T-cell leukemia and lymphoma.
     Haematologica. 2022 May 26. doi: 10.3324/haematol.2021.279542.
     

     >> Share

     
     
143. SARKOZY C, Salles G
     PET-CT before autologous stem cell transplant in follicular lymphoma: coming too late?
     Haematologica. 2022 May 19. doi: 10.3324/haematol.2021.281255.
     

     >> Share

     
     
144. EYRE TA, Barrington SF, Okosun J, Abamba C, et al
     Impact of PET-CT status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplant.
     Haematologica. 2022 May 19. doi: 10.3324/haematol.2021.280287.
     

     >> Share

     
     
145. RIGAUD C, Abbou S, Ducassou S, Simonin M, et al
     Profound and sustained response with next generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement.
     Haematologica. 2022 May 19. doi: 10.3324/haematol.2021.280081.
     

     >> Share

     
     
146. PICOD A, Martino S, Cervera P, Manuceau G, et al
     Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal nasal-type natural killer/T cell lymphoma.
     Haematologica. 2022 May 5. doi: 10.3324/haematol.2021.280349.
     

     >> Share

     
     
147. MEI M, Hamadani M, Ahn KW, Chen Y, et al
     Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit.
     Haematologica. 2022;107:1214-1217.
     

     >> Share

     
     
148. ESCHERICH G, Zur Stadt U, Borkhardt A, Dilloo D, et al
     Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative
     Haematologica. 2022;107:1026-1033.
     

     >> Share

     
     
149. GAO J, Wang MY, Ren Y, Lwin T, et al
     Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.
     Haematologica. 2022;107:1119-1130.
     

     >> Share

     
     April 2022
150. SMELAND K, Holte H, Fagerli UM, Bersvendsen H, et al
     Total late effect burden in long-term lymphoma survivors after highdose therapy with autologous stem-cell transplant and its effect on health-related quality of life.
     Haematologica. 2022 Apr 28. doi: 10.3324/haematol.2021.280413.
     

     >> Share

     
     
151. ARRIBAS AJ, Napoli S, Cascione L, Sartori G, et al
     Resistance to PI3kappadelta inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis.
     Haematologica. 2022 Apr 28. doi: 10.3324/haematol.2021.279957.
     

     >> Share

     
     
152. CLOSE K, Fitzgibbon J
     KDM4C in GC lymphoma: a new piece of the epigenetic puzzle.
     Haematologica. 2022 Apr 28. doi: 10.3324/haematol.2022.280898.
     

     >> Share

     
     
153. TANAKA N, Mori S, Kiyotani K, Ota Y, et al
     Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.
     Haematologica. 2022 Apr 14. doi: 10.3324/haematol.2021.280352.
     

     >> Share

     
     
154. INVERNIZZI R
     Images from the Haematologica Atlas of Hematologic Cytology: precursor lymphoid neoplasms, cytochemistry and immunocytochemistry.
     Haematologica. 2022;107:781.
     

     >> Share

     
     
155. CORREIA E, Cha J, Krishnasamy S, O'Donnell M, et al
     A case series of primary cutaneous B-cell lymphomas with atypical presentations: diagnostic and therapeutic challenges.
     Haematologica. 2022;107:1014-1016.
     

     >> Share

     
     
156. TANAGER KS, Yu J, Chiu BC, Carll TC, et al
     Loss of 5-hydroxymethylcytosine expression is near-universal in B-cell lymphomas with variable mutations in epigenetic regulators.
     Haematologica. 2022;107:966-969.
     

     >> Share

     
     
157. VISENTIN A, Bonaldi L, Rigolin GM, Mauro FR, et al
     The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation.
     Haematologica. 2022;107:868-876.
     

     >> Share

     
     March 2022
158. KIM M, Hwang HS, Yoon DH, Chun SM, et al
     Distinct genetic alterations in Burkitt-like lymphoma with 11q aberration and Burkitt lymphoma: a novel case report of composite lymphoma.
     Haematologica. 2022 Mar 31. doi: 10.3324/haematol.2021.280543.
     

     >> Share

     
     
159. QUIVORON C, Tarabay A, Michot JM, Pages A, et al
     Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B cell lymphoma.
     Haematologica. 2022 Mar 24. doi: 10.3324/haematol.2021.280464.
     

     >> Share

     
     
160. GARCIA-SANCHO AM, Bellei M, Lopez-Parra M, Gritti G, et al
     Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
     Haematologica. 2022 Mar 24. doi: 10.3324/haematol.2021.279426.
     

     >> Share

     
     
161. ELDERING E
     A BAFFling menage a trois in mantle cell lymphoma.
     Haematologica. 2022 Mar 10. doi: 10.3324/haematol.2022.280721.
     

     >> Share

     
     
162. DECOMBIS S, Papin A, Bellanger C, Sortais C, et al
     The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition.
     Haematologica. 2022 Mar 10. doi: 10.3324/haematol.2021.279800.
     

     >> Share

     
     
163. DOURTHE ME, Phulpin A, Auperin A, Bosq J, et al
     Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study.
     Haematologica. 2022 Mar 3. doi: 10.3324/haematol.2021.280257.
     

     >> Share

     
     
164. CANDON S, Lemee V, Leveque E, Etancelin P, et al
     Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas.
     Haematologica. 2022;107:755-758.
     

     >> Share

     
     February 2022
165. BOUARD L, Tessoulin B, Thieblemont C, Bouabdallah K, et al
     Humoral immune-depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma.
     Haematologica. 2022 Feb 17. doi: 10.3324/haematol.2021.279561.
     

     >> Share

     
     
166. KORONA B, Korona D, Zhao W, Wotherspoon AC, et al
     CCR6 activation links innate immune responses to MALT lymphoma development.
     Haematologica. 2022 Feb 10. doi: 10.3324/haematol.2021.280067.
     

     >> Share

     
     
167. CASHEN AF, Bartlett NL
     Stem cell transplant for lymphoma - never too late?
     Haematologica. 2022 Feb 3. doi: 10.3324/haematol.2021.280519.
     

     >> Share

     
     
168. SMITH S
     Too much and not enough: revisiting maintenance rituximab in indolent lymphomas.
     Haematologica. 2022;107:353-354.
     

     >> Share

     
     January 2022
169. WAI CMM, Chen S, Phyu T, Fan S, et al
     Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS.
     Haematologica. 2022 Jan 13. doi: 10.3324/haematol.2021.280003.
     

     >> Share

     
     
170. KOCH K, Richter J, Hanel C, Huttmann A, et al
     Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/transformation.
     Haematologica. 2022 Jan 13. doi: 10.3324/haematol.2021.279351.
     

     >> Share

     
     
171. CHEAH CY, Zucca E, Rossi D, Habermann TM, et al
     Marginal zone lymphoma: present status and future perspectives.
     Haematologica. 2022;107:35-43.
     

     >> Share

     
     
172. QUALLS D, Salles G
     Prospects in the management of patients with follicular lymphoma beyond first-line therapy.
     Haematologica. 2022;107:19-34.
     

     >> Share

     
     
173. CARTRON G, Trotman J
     Time for an individualized approach to first-line management of follicular lymphoma.
     Haematologica. 2022;107:7-18.
     

     >> Share

     
     
174. SMITH SM, Salles G
     Indolent lymphomas: introduction to a series highlighting progress and ongoing challenges.
     Haematologica. 2022;107:4-6.
     

     >> Share

     
     
175. INVERNIZZI R
     Images from the Haematologica Atlas of Hematologic Cytology: Sezary syndrome.
     Haematologica. 2022;107:1.
     

     >> Share

     
     December 2021
176. MAROUF A, Cottereau AS, Kanoun S, Deschamps P, et al
     Outcomes of refractory or relapsed Hodgkin lymphoma patients with post autologous stem cell transplantation brentuximab vedotin maintenance : a French multicenter observational cohort study.
     Haematologica. 2021 Dec 30. doi: 10.3324/haematol.2021.279564.
     

     >> Share

     
     
177. KIM HT, Baker PO, Parry E, Davids M, et al
     Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation.
     Haematologica. 2021;106:3219-3222.
     

     >> Share

     
     November 2021
178. KOHN M, Delord M, Chbat M, Guemriche A, et al
     A third anti-SARS-Cov2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia.
     Haematologica. 2021 Nov 18. doi: 10.3324/haematol.2021.280026.
     

     >> Share

     
     
179. KUNSTNER A, Witte HM, Riedl J, Bernard V, et al
     Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing.
     Haematologica. 2021 Nov 18. doi: 10.3324/haematol.2021.279631.
     

     >> Share

     
     
180. ALBERTSSON-LINDBLAD A, Palsdottir T, Smedby KE, Weibull CE, et al
     Survival in mantle cell lymphoma after frontline treatment with Rbendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017.
     Haematologica. 2021 Nov 18. doi: 10.3324/haematol.2021.279037.
     

     >> Share

     
     
181. STEINER RE, Banchs J, Koutroumpakis E, Becnel M, et al
     Cardiovascular events in patients treated with chimeric antigen receptor t-cell therapy for aggressive B-cell lymphoma.
     Haematologica. 2021 Nov 11. doi: 10.3324/haematol.2021.280009.
     

     >> Share

     
     September 2021
182. CASAGRANDE N, Borghese C, Aldinucci D
     In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases 3D tumor-stroma heterospheroid viability.
     Haematologica. 2021 Sep 9. doi: 10.3324/haematol.2021.279389.
     

     >> Share

     
     
183. KNORR F, Zimmermann M, Attarbaschi A, Kabickova E, et al
     Dose-adjusted EPOCH-Rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.
     Haematologica. 2021 Sep 9. doi: 10.3324/haematol.2021.278971.
     

     >> Share

     
     
184. ROSCHEWSKI M
     Preventing central nervous system spread in diffuse large B-cell lymphoma - novel approaches needed.
     Haematologica. 2021;106:2298-2300.
     

     >> Share

     
     
185. DONG G, Li Y, Lee L, Liu X, et al
     Genetic manipulation of primary human natural killer cells to investigate the functional and oncogenic roles of PRDM1.
     Haematologica. 2021;106:2427-2438.
     

     >> Share

     
     August 2021
186. DUELL J, Maddocks KJ, Gonzalez-Barca E, Jurczak W, et al
     Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
     Haematologica. 2021 Aug 19. doi: 10.3324/haematol.2021.279802.
     

     >> Share

     
     
187. KOSTAKOGLU L, Mattiello F, Martelli M, Sehn LH, et al
     Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.
     Haematologica. 2021 Aug 19. doi: 10.3324/haematol.2021.278663.
     

     >> Share

     
     
188. BASTIDAS TORRES AN, Melchers RC, Van Grieken L, Out-Luiting JJ, et al
     Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma.
     Haematologica. 2021 Aug 12. doi: 10.3324/haematol.263251.
     

     >> Share

     
     
189. KIM M, Lee JO, Koh J, Kim TM, et al
     A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas.
     Haematologica. 2021;106:2277-2280.
     

     >> Share

     
     July 2021
190. GURION R, Rozovski U, Itchaki G, Gafter-Gvili A, et al
     Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.
     Haematologica. 2021 Jul 29. doi: 10.3324/haematol.2021.279216.
     

     >> Share

     
     
191. LIN RJ, Owens CN, Drill E, Iannotta A, et al
     Prephase rituximab/prednisone therapy and aging-related, pro-inflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma
     Haematologica. 2021 Jul 22. doi: 10.3324/haematol.2021.278719.
     

     >> Share

     
     
192. DODERO A, Guidetti A, Marino F, Tucci A, et al
     Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
     Haematologica. 2021 Jul 22. doi: 10.3324/haematol.2021.278638.
     

     >> Share

     
     
193. STRATI P, De Vos S, Ruan J, Maddocks KJ, et al
     Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase 1b study.
     Haematologica. 2021 Jul 8. doi: 10.3324/haematol.2021.278654.
     

     >> Share

     
     
194. RAM R, Grisariu S, Shargian-Alon L, Amit O, et al
     Toxicity and efficacy of chimeric antigen receptor T-cell in patients with diffuse large B cell lymphoma above the age of 70 years compare to younger patients - a matched control multi-center cohort study.
     Haematologica. 2021 Jul 8. doi: 10.3324/haematol.2021.278288.
     

     >> Share

     
     
195. DUELL J, Maddocks KJ, Gonzalez-Barca E, Jurczak W, et al
     Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
     Haematologica. 2021 Jul 1. doi: 10.3324/haematol.2020.275958.
     

     >> Share

     
     June 2021
196. BENKLI CY, Marcogliese AN, Agrusa JE, Adesina AM, et al
     Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients.
     Haematologica. 2021 Jun 24. doi: 10.3324/haematol.2021.278936.
     

     >> Share

     
     
197. EVENS AM, Connors JM, Younes A, Ansell SM, et al
     Older patients (aged >/=60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
     Haematologica. 2021 Jun 24. doi: 10.3324/haematol.2021.278438.
     

     >> Share

     
     
198. NAPOLI S, Cascione L, Rinaldi A, Spriano F, et al
     Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma.
     Haematologica. 2021 Jun 24. doi: 10.3324/haematol.2020.267096.
     

     >> Share

     
     
199. RULE S, Barreto WG, Briones J, Carella AM, et al
     Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the Phase III MabCute study.
     Haematologica. 2021 Jun 17. doi: 10.3324/haematol.2020.274803.
     

     >> Share

     
     
200. PECE R, Tavella S, Costa D, Varesano S, et al
     Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect.
     Haematologica. 2021 Jun 10. doi: 10.3324/haematol.2021.278469.
     

     >> Share

     
     
201. SVOBODA J, Bair SM, Landsburg DJ, Dwivedy Nasta S, et al
     Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
     Haematologica. 2021;106:1705-1713.
     

     >> Share

     
     May 2021
202. DLOUHY I, Armengol M, Recasens-Zorzo C, Ribeiro ML, et al
     Interleukin-1 receptor associated kinase 1/4 and bromodomain and extraterminal inhibitions converge on NF-kappaB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88(L265P) mutati
     Haematologica. 2021 May 13. doi: 10.3324/haematol.2020.278258.
     

     >> Share

     
     
203. PILERI SA, Mazzara S, Derenzini E
     Plasmablastic lymphoma: one or more tumours?
     Haematologica. 2021 May 6. doi: 10.3324/haematol.2021.278841.
     

     >> Share

     
     
204. NIETO Y, Gruschkus S, Valdez BC, Jones RB, et al
     Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis.
     Haematologica. 2021 May 6. doi: 10.3324/haematol.2021.278311.
     

     >> Share

     
     
205. RAMIS-ZALDIVAR JE, Gonzalez-Farre B, Nicolae A, Pack S, et al
     MAP-kinase and JAK-STAT pathways dysregulation in plasmablastic lymphoma.
     Haematologica. 2021 May 6. doi: 10.3324/haematol.2020.271957.
     

     >> Share

     
     April 2021
206. STRAUS DJ
     Progress in understanding the biology of nodular lymphocyte predominant Hodgkin lymphoma.
     Haematologica. 2021 Apr 22. doi: 10.3324/haematol.2021.278785.
     

     >> Share

     
     
207. PASCHOLD L, Willscher E, Bein J, Vornanen M, et al
     Evolutionary clonal trajectories in nodular lymphocyte predominant Hodgkin lymphoma with high transformation risk.
     Haematologica. 2021 Apr 22. doi: 10.3324/haematol.2021.278427.
     

     >> Share

     
     February 2021
208. BOBILLO S, Crespo M, Escudero L, Mayor R, et al
     Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas.
     Haematologica. 2021;106:513-521.
     

     >> Share

     
     March 2020
209. WANG Y, Tschautscher MA, Rabe KG, Call TG, et al
     Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.
     Haematologica. 2020;105:765-773.
     

     >> Share

     
     January 2020
210. STRATI P, Nastoupil LJ, Davis RE, Fayad LE, et al
     A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas.
     Haematologica. 2020;105:e26-e28.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share